Clearmind Medicine says US publishes MDMA-PEA patent application for PTSD treatment
Reuters2026/08/24 12:04- Clearmind reported U.S. publication of its patent application covering a combination of MDMA and N-acylethanolamines for treating PTSD.
- Application also targets anxiety and eating disorders; palmitoylethanolamide cited as a lead N-acylethanolamine in the claimed methods.
- Collaboration with NeuroThera integrates its PEA technology; partners now cite 13 joint patent applications filed globally.
- Clearmind flagged potential to improve MDMA treatment economics via lower dosing, fewer side effects, and a wider therapeutic window.
- Disclosure follows FDA final guidance dated July 13, 2026, outlining clinical development considerations for psychedelic drugs, including MDMA.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold Drops 5.5% From 3-Month High but Goldman Sachs Still Sees 10% Upside
Wella Company (WELA.US), a beauty brand holding company under KKR, applies for a U.S. IPO aiming to raise over $500 million.
According to disclosure documents from the US Securities and Exchange Commission (SEC), KKR's beauty brand holding company, Wella Company (WELA.US), officially submitted its initial public offering (IPO) application this Monday. The market expects its fundraising scale to exceed 500 millions USD.
Arista Networks Insider Sold Shares Worth $60,780,047, According to a Recent SEC Filing
Crypto prices
More
